Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer

ABSTRACT: Interventions: Capecitabine plus bevacizumab therapy Capecitabine:2,000mg/m2 twice daily (orally, day1 after dinner:day8 after breakfast) Bevacizumab:7.5mg/kg day 1 The treatment is repeated every three weeks until disease progression or severe toxicity. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced And/or Recurrent Colorectal Cancer

PROVIDER: 2625591 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR